DK3536339T3 - Fremgangsmåde til forbedring af astmasymptomer ved anvendelse af benralizumab - Google Patents

Fremgangsmåde til forbedring af astmasymptomer ved anvendelse af benralizumab Download PDF

Info

Publication number
DK3536339T3
DK3536339T3 DK19162585.4T DK19162585T DK3536339T3 DK 3536339 T3 DK3536339 T3 DK 3536339T3 DK 19162585 T DK19162585 T DK 19162585T DK 3536339 T3 DK3536339 T3 DK 3536339T3
Authority
DK
Denmark
Prior art keywords
benralizumab
procedure
asthma symptoms
improving asthma
improving
Prior art date
Application number
DK19162585.4T
Other languages
English (en)
Inventor
Christine Ward
Lorin Roskos
Bing Wang
Donald Raible
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of DK3536339T3 publication Critical patent/DK3536339T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK19162585.4T 2013-08-12 2014-08-07 Fremgangsmåde til forbedring af astmasymptomer ved anvendelse af benralizumab DK3536339T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361864950P 2013-08-12 2013-08-12
EP14836392.2A EP3033103B1 (en) 2013-08-12 2014-08-07 Methods for improving asthma symptoms using benralizumab

Publications (1)

Publication Number Publication Date
DK3536339T3 true DK3536339T3 (da) 2021-12-20

Family

ID=52448839

Family Applications (2)

Application Number Title Priority Date Filing Date
DK19162585.4T DK3536339T3 (da) 2013-08-12 2014-08-07 Fremgangsmåde til forbedring af astmasymptomer ved anvendelse af benralizumab
DK14836392.2T DK3033103T3 (da) 2013-08-12 2014-08-07 Fremgangsmåde til forbedring af astmasymptomer ved anvendelse af benralizumab

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK14836392.2T DK3033103T3 (da) 2013-08-12 2014-08-07 Fremgangsmåde til forbedring af astmasymptomer ved anvendelse af benralizumab

Country Status (18)

Country Link
US (1) US9441047B2 (da)
EP (3) EP3988114A1 (da)
JP (2) JP6803229B2 (da)
KR (1) KR102337601B1 (da)
CN (2) CN111617244A (da)
AU (3) AU2014306960B2 (da)
BR (1) BR112016002462A8 (da)
CA (1) CA2918050C (da)
DK (2) DK3536339T3 (da)
ES (2) ES2901634T3 (da)
HK (1) HK1221647A1 (da)
HU (2) HUE057065T2 (da)
MX (1) MX368474B (da)
PL (2) PL3536339T3 (da)
RU (1) RU2728578C2 (da)
SG (1) SG11201600484TA (da)
TR (1) TR201910413T4 (da)
WO (1) WO2015023508A2 (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9441046B2 (en) * 2013-08-12 2016-09-13 Astrazeneca Ab Methods for increasing forced expiratory volume in asthmatics using benralizumab
CA2918105C (en) 2013-08-12 2023-02-28 Medimmune, Llc Methods for reducing exacerbation rates of asthma using benralizumab
KR20160061352A (ko) * 2013-10-15 2016-05-31 메디뮨 엘엘씨 벤랄리주맙을 사용하여 만성 폐쇄성 폐 질환을 치료하는 방법
SI3060229T1 (sl) 2013-10-24 2021-11-30 Astrazeneca Ab Stabilne vodne formulacije protiteles
JP2018538249A (ja) 2015-11-04 2018-12-27 アストラゼネカ アクチボラグ 好酸球性疾患における好酸球標的化治療薬に対する臨床応答の予測変数としてのジペプチジルペプチダーゼ−４およびペリオスチン
US20180056018A1 (en) * 2016-08-31 2018-03-01 Cephalon, Inc. Inhalation Systems, Devices and Methods
TW202214692A (zh) * 2020-06-05 2022-04-16 瑞典商阿斯特捷利康公司 治療患有鼻瘜肉的患者的重度氣喘之方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1241944C (zh) 1995-09-11 2006-02-15 协和发酵工业株式会社 抗人白介素－5受体α链的抗体
US6746839B1 (en) * 1998-01-12 2004-06-08 Interleukin Genetics, Inc. Diagnostics and therapeutics for an obstructive airway disease
EP1176195B1 (en) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US7404953B2 (en) 2000-02-15 2008-07-29 Kyowa Hakko Kogyo Co., Ltd. Methods using eosinophil-specific apoptosis inducer
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
AU2004279740A1 (en) 2003-10-08 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Antibody composition specifically binding to IL-5 receptor
US20060014680A1 (en) 2004-07-13 2006-01-19 Caiding Xu Peptides and compounds that bind to the IL-5 receptor
WO2007041635A2 (en) 2005-10-03 2007-04-12 Xencor, Inc. Fc variants with optimized fc receptor binding properties
HUE036885T2 (hu) 2007-05-14 2018-08-28 Astrazeneca Ab Eljárás a bazofil-szint csökkentésére
TWI732259B (zh) 2010-12-16 2021-07-01 美商建南德克公司 關於th2抑制作用之診斷及治療
EP2710370A4 (en) * 2011-05-18 2015-01-07 Medimmune Llc METHODS OF DIAGNOSING AND TREATING PULMONARY DISEASES OR DISORDERS
HK1201440A1 (en) 2011-11-01 2015-09-04 Medimmune, Llc Methods for reducing the frequency and severity of acute exacerbations of asthma
CA2918105C (en) 2013-08-12 2023-02-28 Medimmune, Llc Methods for reducing exacerbation rates of asthma using benralizumab
US9441046B2 (en) * 2013-08-12 2016-09-13 Astrazeneca Ab Methods for increasing forced expiratory volume in asthmatics using benralizumab

Also Published As

Publication number Publication date
AU2014306960A1 (en) 2016-02-04
EP3033103A4 (en) 2017-03-22
HK1225303A1 (en) 2017-09-08
US9441047B2 (en) 2016-09-13
KR102337601B1 (ko) 2021-12-10
AU2014306960B2 (en) 2020-01-16
RU2016108734A3 (da) 2018-06-18
TR201910413T4 (tr) 2019-08-21
HUE057065T2 (hu) 2022-04-28
SG11201600484TA (en) 2016-02-26
CA2918050C (en) 2023-10-03
DK3033103T3 (da) 2019-08-05
WO2015023508A2 (en) 2015-02-19
JP2016527326A (ja) 2016-09-08
ES2901634T3 (es) 2022-03-23
BR112016002462A8 (pt) 2018-06-12
EP3033103A2 (en) 2016-06-22
MX368474B (es) 2019-10-04
RU2016108734A (ru) 2017-09-19
EP3536339B1 (en) 2021-10-06
WO2015023508A3 (en) 2015-04-16
JP6803229B2 (ja) 2020-12-23
JP2020100653A (ja) 2020-07-02
BR112016002462A2 (pt) 2017-09-12
EP3536339A1 (en) 2019-09-11
CN105451761A (zh) 2016-03-30
MX2016001195A (es) 2016-07-21
AU2020202564A1 (en) 2020-05-07
RU2020123894A (ru) 2020-09-18
WO2015023508A8 (en) 2015-10-15
ES2740355T3 (es) 2020-02-05
RU2728578C2 (ru) 2020-07-30
CA2918050A1 (en) 2015-02-19
CN111617244A (zh) 2020-09-04
PL3033103T3 (pl) 2019-10-31
PL3536339T3 (pl) 2022-02-21
US20150044204A1 (en) 2015-02-12
EP3033103B1 (en) 2019-06-05
AU2023214323A1 (en) 2023-10-19
HUE045402T2 (hu) 2019-12-30
HK1221647A1 (zh) 2017-06-09
KR20160042123A (ko) 2016-04-18
EP3988114A1 (en) 2022-04-27

Similar Documents

Publication Publication Date Title
HUS2400016I1 (hu) FCRN elleni antitestek
DK3076967T3 (da) Fremgangsmåder til behandling af residuelle symptomer på skizofreni
DK3512197T3 (da) Fremgangsmåde til kortlægning af intraprædikationsmodus
DK3225604T3 (da) Fremgangsmåde til fremstilling af flerlagsruder
DK2804548T3 (da) Apparat til okklusionsfjernelse
HUE038813T2 (hu) Eljárás rontó káprázás javítására
FI20135770L (fi) Prosessi hiilivetyjen valmistamiseksi
DK2941484T3 (da) Fremgangsmåde til at opnå immunsuppressive dendritriske celler
FI20125613L (fi) Menetelmä ligniinin fraktioimiseksi
FI20136031A7 (fi) Prosessi hiilivetyjen valmistamiseksi
FI20125708L (fi) Prosessi hiilivetyjen valmistamiseksi
DK2836460T3 (da) Fremgangsmåde til fremstilling af graphen
DK2872891T3 (da) Risikostratificering ved influenza
DK3536339T3 (da) Fremgangsmåde til forbedring af astmasymptomer ved anvendelse af benralizumab
DK2870252T3 (da) Fremgangsmåder ved anvendelse af patatin
FI20135223L (fi) Prosessi bioöljyn konvertoimiseksi
HRP20190123T1 (hr) Postupak pročišćavanja saponina
DK2834229T3 (da) Fremgangsmåde til fremstilling af ccr3-inhibitorer
DK3033104T3 (da) Fremgangsmåder til forøgelse af forceret eksspiratorisk volumen hos astmatikere ved anvendelse af benralizumab
DK3050961T3 (da) Fremgangsmåde til forbedring af effektiviteten ved inducering af pluripotente stamceller
DK2809782T3 (da) Forbedret fremgangsmåde til fremstilling af makrokugler
EP2838629A4 (en) EXTRACTOR
DK2925854T3 (da) Fremgangsmåde til forbedring af gærstammer
DK2872536T3 (da) Fremgangsmåde til ekstraktion af biomasse
DK3202769T3 (da) Fremgangsmåde til oprensning af phosphaplatinforbindelser